Tegafur,Gimeracil and Oteracil Potassium

The NEOSUMMIT-03 phase 2 trial achieved its primary endpoint with 50% of patients showing major pathological response to perioperative tislelizumab plus chemotherapy in locally advanced gastroesophageal junction adenocarcinoma.

A phase 2 trial combining fruquintinib and trifluridine/tipiracil demonstrated clinical activity in heavily pretreated metastatic colorectal cancer (mCRC) patients.

Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.

A groundbreaking study demonstrates that patient-derived organoids (PDOs) can accurately predict chemotherapy responses in esophageal squamous cell carcinoma (ESCC) patients with 83.33% accuracy. The research, involving 55 patient samples, establishes PDOs as a potential tool for personalizing cancer treatment strategies.

The SOXRC regimen, combining camrelizumab and rivoceranib with chemotherapy, demonstrates superior pathological responses in advanced gastric cancer patients compared to chemotherapy alone.